cancer centers. [10] [11] [12] [13] [14] This report describes the 100-day treatment-related mortality (TRM) of the first 1000 consecutive patients receiving high-dose myeloablative chemotherapy High-dose chemotherapy (HDC) with autologous peripheral blood progenitor cell (PBPC) is being increaswithin a multicentered community-based clinical trials program. ingly utilized as a therapeutic modality for patients with chemotherapy-sensitive disease. Several published HDC regimens have become relatively widely used. The purpose of this analysis was to determine treatment-related Materials and methods mortality (TRM) following administration of five different HDC regimens in community cancer centers. A
11,13
High-dose chemotherapy (HDC) is increasingly utilized to Apheresis was performed daily with a continuous flow centreat patients with a variety of chemotherapy sensitive distrifuge (Fenwal CS-3000; Baxter, Deerfield, IL, USA) for eases including: malignant lymphoma, multiple myeloma, 3-4 h sessions processing 10 l of whole blood per session. 11 breast and ovarian cancer. [1] [2] [3] [4] [5] [6] [7] [8] [9] The development of the techThe number of CD34 + cells was evaluated in each pronology for peripheral blood progenitor cell (PBPC) support duct using anti-HPCA-2 antibody (Becton Dickson, Mounand the earlier hematopoietic recovery as compared to bone tain View, CA, USA) as the primary antibody followed by marrow (BM) has led to the delivery of HDC in community FITC conjugated goat antimouse antibody. The final product containing 10% DMSO in autologous platelet-deficient plasma was frozen in a liquid nitrogen Gordinier controlled and was maintained in the vapor phase of liquid nitrogen below −130°C. 13 Cryopreserved PBPC were thawed and bilirubin Ͼ2 mg/dl and/or histologically by damaged endoinfused 48-72 h after the last dose of chemotherapy. 12 The thelial cells of the terminal hepatic venulae, dilatation of day of PBPC infusion was designated day 0.
the sinusoids and necrosis of hepatocytes. 18 Idiopathic pneumonia syndrome (IPS) was defined as diffuse pulmonary infiltrates not associated with pulmonary edema or an Treatment regimens identifiable infectious cause. were given empirically for a hemoglobin Ͻ8.5 mg/dl and a and one with HD were administered busulfan 12 mg/kg (4 platelet count р20 × 10 9 /l, respectively. All blood products mg/kg/day orally × 3), melphalan 100 mg/m 2 (50 were irradiated to 2500 cGy prior to their administration. mg/m 2 /day × 2), and thiotepa 500 mg/m 2 (250 mg/m 2 /day Indwelling catheters were instilled daily with a solution × 2). 14, 16 containing heparin 5000 U/ml and vancomycin 25 g/ml, with the solution aspirated and discarded at each change. 21 Ifosfamide, carboplatin and etoposide (ICE): Thirty-five Nine hundred and thirty-eight patients (94%) received Gpatients (22 with sarcoma, three with NHL, one with meta-CSF (n = 809) or granulocyte-macrophage colony-stimulatstatic breast cancer, and two with HD) were treated with ing factor (GM-CSF) (n = 129) after PBPC infusion until ifosfamide 10 g/m 2 (2.5 g/m 2 as a 24 h continuous infusion the ANC was Ͼ0.5 × 10 9 /l for 3 consecutive days. Sixtyon days −6 and −3), etoposide 1400 mg/m 2 (350 mg/m 2 /day two patients did not receive a growth factor after PBSC i.v. over 3 h), and carboplatin 1200 mg/m 2 , (300 mg/m 2 /day infusion for the following reasons: 42 patients received i.v. over 2 h on days −6 and −3).
HDC before G-or GM-CSF was on the market, 18 were randomized on a study to receive no growth factors and Busulfan and cyclophosphamide (BuCy): Twenty-nine two patients with AML did not receive a growth factor by patients (21 with multiple myeloma, four with acute study design. myeloid leukemia (AML), and 10 with NHL were treated with busulfan 16 mg/kg (4 mg/kg/day orally × 4) and cyclophosphamide 120 mg/kg (60 mg/day i.v. on days −3 and −2).
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Statistical analysis
Definitions
All data were collected using a custom-developed, distributed database that was installed in each of the 28 participatNeutrophil engraftment was defined as the first of 2 coning sites. Data was collected and entered on site and audited secutive days on which the absolute neutrophil count by a central clinical trials staff in Memphis, TN, USA. (ANC) exceeded 0.5 × 10 9 /l following the nadir. Platelet Evaluation of cause of death was performed by two phystransfusion independence was defined as the first of 7 conicians using clinical, laboratory, biopsy and autopsy crisecutive days on which the platelet count exceeded teria. Data were analyzed using the SAS statistical package 20.0 × 10 9 /l unsupported by transfusions. Treatment-related version 6.04 (SAS Institute, Cary, NC, USA). Multivariate mortality was defined as any death, not attributable preanalysis was performed using a logistic regression model dominantly to progressive disease, within 100 days of with step-wise selection of variables. CD34 + cell dose was PBPC infusion. modeled using a log transform to improve the line counts Veno-occlusive disease (VOD) of the liver was defined of the data. 13 All proportions were compared using a 2 as liver toxicity secondary to chemotherapy. VOD was significance test. Means were compared using a Student's diagnosed clinically by hepatomegaly and/or liver tenderness, weight gain Ͼ2% of baseline, and an elevated serum t-test. Eight patients died before neutrophil engraftment. The
673
Performance status median time to achieve an ANC Ͼ0.5 × 10 9 /l in the remain-0 848 (84) ing patients was 10 days (range 7-23). Eleven patients died 1 147 (15) before achieving platelet transfusion independence. The
median day to achieve a platelet count Ͼ20 × 10 9 /l in the Disease remaining patients was 9 (range 4-68). 
100-day treatment related mortality
Ovarian cancer 43 (5) Hodgkin's disease 34 (3) Results are summarized in Tables 3 and 4 . Fifty-nine
Non-Hodgkin's lymphoma 176 (17) patients (5.9%) died within 100 days of PBPC infusion.
Twenty-five patients (2.5%) with advanced and usually
Prior radiotherapy 267 (27) refractory disease died predominantly of causes related to (3.4%) died from TRM and the causes of death are summarized in Table 4 . Fifteen deaths (1.5%) were directly attributable to infection. Four patients died of bacterial and four of Candida Results sepsis. Two patients died on days +5 and +7 with fever and hypotension refractory to fluid administration and vasoPatient and treatment characteristics pressor support, but without isolation of infectious organism. Autopsies were not performed on these two patients Patient and treatment characteristics are shown in Tables 1 and these deaths were considered infectious in etiology. and 2, respectively.
Two patients died of CMV infection on day +31 and +51, respectively. One patient died of invasive pulmonary Aspergillosis on day +25 and one patient died from a gastrointestinal perforation with invasive Candida at autopsy.
Variable No. (%)
One patient died of PCP on day +90. All three patients dying from CMV or PCP had normal neutrophil counts at Regimen the time of death.
Carmustine, etoposide, cytarabine, 173 (17) Nineteen patients (1.9%) died from regimen-related tox- Results of the univariate analysis are presented in Table   TRM = treatment-related mortality.
3. Multivariate analysis was performed for the endpoint 100 674 day TRM. Variables entered included disease, performance with 100 day TRM. Twenty-one of 317 (6.6%) patients Ͻ50 years of age vs 1.9% (13 of 683) of patients Ͻ50 years status (0-1 vs у2), treatment regimen, administration of a post-PBPC infusion growth factor, gender, number of prior of age experienced TRM before 100 days (P = 0.0008). Seventeen of 275 patients (6.2%) between 51 and 60 years chemotherapy (0-1 vs у2) regimens, history of prior radiation, the year of center operation, and the year of treatof age and four of 42 patients (9.5%) Ͼ60 years of age died from TRM within 100 days of PBPC infusion. ment. Age and log of the number of CD34 + cells/kg infused were entered as continuous variables. Age (P = 0.001),
The second significant variable predicting for 100 day TRM in the multivariate analysis was the preparative regi-CD34 cells/kg (P = 0.003) and the regimen CTCb (P = 0.0001) were found to significantly influence the 100-day men with a reduced risk of mortality observed with CTCb. Thirteen of 707 patients (1.8%) experienced TRM before TRM by multivariate analysis.
Age was the single most powerful variable associated 100 days vs 21 of 293 (7.2%) of patients receiving other autologous BM transplantation is 2-8%. [31] [32] [33] This difference probably reflects a more prevalent use of CMV negative blood products or leukocyte filtration devices in CMV seronegative patients in the current study. [34] [35] [36] In addition, the higher incidence of CMV has occurred in patients with preparative regimens (P = 0.0001). The regimen-specific 100-day TRM rates were: BEAC (7.5%), BuCy (5.7%), hematologic malignancies and not in patients with solid tumors who make up the majority of patients in the current BuMelT (7.1%), CTCb (1.8%), and ICE (6.9%).
A third significant variable was the number of CD34 + study.
31-33
Regimen-related toxicities were responsible for death in cells infused per kilogram of body weight. The 100-day TRM as a function of CD34 + cells is displayed in dying on day +11 and +15, prior to recovery of platelets, from an intracerebral hemorrhage and gastrointestinal CD34 + cells/kg experienced mortality within 100 days of treatment. Treatment-related mortality was 2/69 (3%) in bleeding, respectively. Eleven patients died from IPS which may represent lung centers treating Ͻ10 patients per year as compared to 19/514 (4%) and 12/4176 (3%) in centers treating [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] injury from carmustine and cyclophosphamide-containing regimens and has been associated with mortality rates up and Ͼ20 patients per year respectively. to 30%. 19, 22, 37, 38 Fatal IPS is typically associated with higher doses of carmustine (600 mg/m 2 ), and the observed incidence in the current study is consistent with that Discussion reported in the literature for a dose of 300 mg/m 2 . 19, 37 Veno-occlusive disease is also associated with high-dose In this study, patients treated consecutively over a 5-year period were analyzed to determine the early mortality assoalkylator therapy and was the cause of death of three patients in this series. 39 ciated with five published HDC regimens administered in community cancer centers. Six percent of all patients died Multivariate analysis revealed that age, preparative regimen, and CD34 + cell dose significantly influenced the risk within the first 100 days of HDC administration. Twentyfive of these patients (2.5%) died predominantly of compliof 100-day TRM. The effect of age appears to be independent of prior treatment, performance status and CD34 + cations related to disease progression. It is always difficult, however, to assign specific causes of death in patients with cell content of the PBPC collection. Patients under the age of 50 tolerated HDC extremely well as evidenced by a 100-refractory malignancies and HDC could have contributed to death in some of these patients. Thirty-four (3.4%) of day TRM of 1.9%. This risk increases to 6.2% and 9.5% in the sixth and seventh decade of life, respectively. This patients died as a direct consequence of the treatment with approximately half dying of infection and half dying of increased risk of TRM with advancing age in patients receiving HDC should be carefully considered in the RRT.
These mortality rates are not excessive when compared assessment of HDC as a treatment alternative in the older patient populations. to published reports of each separate treatment regimen evaluated. 14, [22] [23] [24] However, it is impossible to accurately The relative risk of dying was decreased in patients treated with high-dose CTCb compared to other treatment compare mortality rates observed in the current analysis with published reports given the wide variation in criteria regimens. The TRM rate of 1.8% with CTCb reported in this series is very low and equivalent to the 2% TRM for patient selection and differences in stem cell sources and doses.
reported previously with a similar regimen using autologous BM for hematopoietic reconstitution. 40 This suggests The mortality rate from infection (1.5%) was low suggesting that PBPC may have reduced the risk of mortality that PBPC have not significantly altered the mortality associated with CTCb. This low TRM following CTCb could from infection as compared to the use of BM. Infections, however, still accounted for 44% of all TRM. Four patients also be entirely due to the relatively good condition of result in delayed neutrophil, platelet and immune recovery affecting TRM. Performance status, disease, gender, amount of prior References chemotherapy, and the administration of a post-PBPC infusion growth factor were not associated with significant
